Advertisement

The stock of Cambridge biopharmaceutical company Zalicus Inc. took a 33 percent dive on Monday after the company announced it’s stopping trials of Synavive, which it had hoped would improve on drugs now on the market to treat rheumatoid arthritis.

Advertisement
Advertisement